D-Finitive Technologies Names Chief Scientific Officer.CHARLESTON, S.C. -- Paul J. Price, Ph.D. has been named the chief scientific officer of D-Finitive Technologies, Inc., a Charleston-based biotechnology company focused on cord blood stem cell research. Dr. Price, who recently retired from GIBCO GIBCO Grand Island Biological Company (tissue culture media enterprise) Invitrogen, has been active in the areas of cell culture and media development since 1958. Dr. Price received his Ph.D. from George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. where he majored in cell biology, biochemistry and virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression . Prior to joining GIBCO Invitrogen in 1990, he was a Founder and Executive Vice President of Hycor Biomedical. This followed his tenure as a branch chief at the Center for Infectious Diseases, a division of the Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. . As part of the Research and Development team at GIBCO Invitrogen, Dr. Price helped design and develop much of their specialized media for the culture of neurons, stem cells and other mammalian cells. Dr. Price has been an active member of the Society for In Vitro Biology (SIVB SIVB Society for In-Vitro Biology ) since 1959 and a member of their board since 1998. He is currently the President of the SIVB. He has been a reviewer for In Vitro magazine and other journals, as well as an outside expert for grant reviews for the National Cancer Institute. Dr. Price has served as an adjunct professor at several universities. He sits on several scientific advisory boards and speaks regularly around the world on cell culture-related topics. Founded in 2005 by D. P. DeLuca, Sr. and D.P. DeLuca, Jr., D-Finitive Technologies works closely with its affiliates, The Medical University of South Carolina “MUSC” redirects here. For Abel Santa María airport in Santa Clara, Cuba (ICAO code MUSC), see Abel Santa María Airport. The Medical University of South Carolina and Clemson University, to further research on the use of cord blood stem cells cord blood stem cells Umbilical cord blood Hematology A therapeutic 'agent' containing concentrated hematopoietic stem cells for Pts with BM depleted–'wiped out' by disease; they are transfused into HLA-identical siblings and used to reconstitute the BM of in Regenerative Medicine, and the application of stem cells to practical disease treatment. This affiliation between medical research and private industry is unique in the state of South Carolina. D-Finitive Technologies also collaborates with researchers at other institutions around the world to promote and foster the study of cord blood stem cells for use in treating human disease. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion